Fungal systemic infections are common in patients with weakened immune system, including immunosuppression and acquired immunodeficiency syndrome (AIDS) patients. Systemic signs consolidate apnea, guaiac-positive stools, abdominal distension, hyperglycemia, leukemoid reaction, hypotension, and others. The treatment of systemic candidiasis and aspergillos need parenteral antifungal therapy and this condition is associated with high mortality rate. Furthermore, this infection may result in permanent neurodevelopmental deficits in long-term survivors.
Market Overview and Dynamics
The North America Systemic Aspergillosis and Systemic Candidasis market is projected to reach US$ 3,352.62 million by 2027 from US$ 2,423.82 million in 2019; it is estimated to grow with a CAGR of 4.2% from 2020 to 2027. The growth of the North America systemic aspergillosis and systemic candidasis market is attributed to the rise in prevalence of fungal diseases, rising hospital acquired fungal infection. However, increasing resistance to antifungal drugs, side effects of antifungal drugs limits the growth of market in this region. Countries in North America are expecting to witness huge challenge due to growing COVID-19. Due to outbreak of disease, healthcare industries has been affected badly. Due to growing COVID-19 cases, many business related activities such as product launches and product promotion conferences has been postponed, leading to restraining the growth of the market.
Key Market Segments
Based on type, the North America systemic aspergillosis and systemic candidasis market is segmented into voriconazole, liposomal, amphotericin b, systemic oral azoles, topical, antifungal agents, and others. In 2019, the systemic oral azoles segment held a larger share of the market. And is expected to grow at a faster rate during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to while preparing the North America systemic aspergillosis and systemic candidasis Market report are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
To understand the North America systemic aspergillosis and systemic candidasis market landscape and identify market segments that are most likely to guarantee a strong return
To stay ahead in comprehending the ever-changing competitive landscape of the North America systemic aspergillosis and systemic candidasis market
To efficiently plan M&A and partnership deals in the North America systemic aspergillosis and systemic candidasis market by identifying market segments with the most promising probable sales
To help take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segments in the North America systemic aspergillosis and systemic candidasis market
To obtain market revenue forecast from 2019 to 2027 in various segments of the North America systemic aspergillosis and systemic candidasis market
NORTH AMRICA SYSTEMIC ASPERGILLOSIS AND SYSTEMIC CANDIDASIS MARKET SEGMENTATION
By Type
Systemic Oral Azoles
Voriconazole
Liposomal Amphotericin B
Topical Antifungal Agents
Others
By Application
Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic Pulmonary Aspergillosis (CPA)
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Others
By Country
US
Canada
Mexico
Company Profiles
Novartis AG
Sanofi
Pfizer Inc.
Merck & Co., Inc.
Bayer AG
Astellas Pharma Inc.
GlaxoSmithKline plc.
Abbott
Cipla Inc.
ENZON PHARMACEUTICALS, INC.
North America Systemic Aspergillosis and Systemic Candidasis Market Strategic Insights
Get more information on this report
North America Systemic Aspergillosis and Systemic Candidasis Market Segmentation Analysis
North America Systemic Aspergillosis and Systemic Candidasis Market Report Highlights
North America Systemic Aspergillosis and Systemic Candidasis Report Scope
Report Attribute
Details
Market size in 2019
US$ 2,423.82 Million
Market Size by 2027
US$ 3,352.62 Million
CAGR (2020 - 2027)
4.2%
Historical Data
2017-2018
Forecast period
2020-2027
Segments Covered
By Type
Voriconazole
Liposomal
Amphotericin B
Systemic Oral Azoles
Topical
Antifungal Agents
By Application
Chronic
Pulmonary Aspergillosis
Allergic
Bronchopulmonary Aspergillosis
Gastrointestinal Candidiasis
Genitourinary Tract Candidiasis
Regions and Countries Covered
North America
US
Canada
Mexico
Market leaders and key company profiles
Novartis AG
Sanofi
Pfizer Inc.
Merck & Co., Inc.
Bayer AG
Astellas Pharma Inc.
GlaxoSmithKline plc.
Abbott
Cipla Inc.
Enzon Pharmaceuticals, Inc.
Get more information on this report
North America Systemic Aspergillosis and Systemic Candidasis Market Country and Regional Insights
Get more information on this report
Identical Market Reports with other Region/Countries
The List of Companies - North America Systemic Aspergillosis and Systemic Candidasis Market
Novartis AG
Sanofi
Pfizer Inc.
Merck & Co., Inc.
Bayer AG
Astellas Pharma Inc.
GlaxoSmithKline plc.
Abbott
Cipla Inc.
Enzon Pharmaceuticals, Inc.
Frequently Asked Questions
How big is the North America Systemic Aspergillosis and Systemic Candidasis Market?
The North America Systemic Aspergillosis and Systemic Candidasis Market is valued at US$ 2,423.82 Million in 2019, it is projected to reach US$ 3,352.62 Million by 2027.
What is the CAGR for North America Systemic Aspergillosis and Systemic Candidasis Market by (2020 - 2027)?
As per our report North America Systemic Aspergillosis and Systemic Candidasis Market, the market size is valued at US$ 2,423.82 Million in 2019, projecting it to reach US$ 3,352.62 Million by 2027. This translates to a CAGR of approximately 4.2% during the forecast period.
What segments are covered in this report?
The North America Systemic Aspergillosis and Systemic Candidasis Market report typically cover these key segments-
What is the historic period, base year, and forecast period taken for North America Systemic Aspergillosis and Systemic Candidasis Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Systemic Aspergillosis and Systemic Candidasis Market report:
Historic Period : 2017-2018
Base Year : 2019
Forecast Period : 2020-2027
Who are the major players in North America Systemic Aspergillosis and Systemic Candidasis Market?
The North America Systemic Aspergillosis and Systemic Candidasis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
Novartis AG
Sanofi
Pfizer Inc.
Merck & Co., Inc.
Bayer AG
Astellas Pharma Inc.
GlaxoSmithKline plc.
Abbott
Cipla Inc.
Enzon Pharmaceuticals, Inc.
Who should buy this report?
The North America Systemic Aspergillosis and Systemic Candidasis Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the North America Systemic Aspergillosis and Systemic Candidasis Market value chain can benefit from the information contained in a comprehensive market report.
Get Free Sample For North America Systemic Aspergillosis and Systemic Candidasis Market
